sign free newsletters sign free newsletters experimental drug biogen idec treatment significantly slow cognitive decline reduce brain amyloid plaque patients early mild forms disease bill berkrot reuters experimental drug biogen idec alzheimer treatment significantly slow cognitive decline reduce brain amyloid plaque patients early mild forms disease according small study likely reignite hopes treatment alzheimer expected strike 75 million people worldwide 2030 effective treatments likely costing billions dollars year care successful treatment pay richest rewards medicine biogen entering field littered expensive failures players pfizer inc eli lilly co. 166 patient trial biogen drug aducanumab tested groups received different dose fifth group